Recommendations for initial evaluation, staging, and response assessment of Hodgkin and XXXX : the Lugano classification.

@entity1 @entity706 @entity5 @entity1892 @entity1893 @entity978
The purpose of this work was to modernize recommendations for evaluation, staging, and response assessment of @entity1 with @entity978 ( @entity978 ) and @entity1893 ( @entity1893 ). A workshop was held at the 11th International Conference on @entity706 in Lugano, Switzerland, in June 2011, that included leading hematologists, oncologists, radiation oncologists, pathologists, radiologists, and nuclear medicine physicians, representing major international @entity706 clinical trials groups and @entity5 centers. Clinical and imaging subcommittees presented their conclusions at a subsequent workshop at the 12th International Conference on @entity706 , leading to revised criteria for staging and of the International Working Group Guidelines of 2007 for response. As a result, fluorodeoxyglucose (FDG) positron emission tomography (PET)   computed tomography (CT) was formally incorporated into standard staging for FDG-avid @entity706 . A modification of the Ann Arbor descriptive terminology will be used for anatomic distribution of disease extent, but the suffixes A or B for symptoms will only be included for @entity978 . A bone marrow biopsy is no longer indicated for the routine staging of @entity978 and most diffuse large @entity1892 . However, regardless of stage, general practice is to treat @entity1 based on limited (stages I and II, nonbulky) or advanced (stage III or IV) disease, with stage II bulky disease considered as limited or advanced disease based on histology and a number of prognostic factors. PET-CT will be used to assess response in FDG-avid histologies using the 5-point scale. The product of the perpendicular diameters of a single node can be used to identify progressive disease. Routine surveillance scans are discouraged. These recommendations should improve evaluation of @entity1 with @entity706 and enhance the ability to compare outcomes of clinical trials.
